Assessment and treatment of depression: a review in high-risk populations.
Hegadoren
Kathy M
KM
University of Alberta, Edmonton, Alberta, Canada. Kathy.hegadoren@ualberta.ca
D000928:Antidepressive Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D017850:Economics, Pharmaceutical; D019317:Evidence-Based Medicine; D014943:Global Health; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000451:nursing; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D014179:Neurotransmitter Uptake Inhibitors / Q000627:therapeutic use; D024802:Nurse's Role; D009730:Nursing Assessment / Q000379:methods*; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D011613:Psychotherapy; D011788:Quality of Life; D012307:Risk Factors; D012944:Social Support; D016896:Treatment Outcome; D014945:Wound Healing
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D014179:Neurotransmitter Uptake Inhibitors